

## Stella Burnside - Chief Executive

---

**From:** Campbell, Dr Henrietta [Henrietta.Campbell@altnagelvin.com] [redacted]  
**Sent:** 03 June 2004 16:13  
**To:** Stella Burnside - Chief Executive  
**Subject:** RE:

**Importance:** High

Dear Stella

Thank you for this. I am not sure how much further the media will want to take this. Let me know if you are approached.

Kind regards, Etta

-----Original Message-----

**From:** Stella Burnside - Chief Executive  
[mailto:SBurnside@altnagelvin.com] [redacted]  
**Sent:** 03 June 2004 12:56  
**To:** henrietta.campbell@altnagelvin.com [redacted]  
**Subject:**  
**Importance:** High

Etta

Having looked at the draft transcript of your interview, which was sent, I am concerned that there may be some ambiguity over facts regarding Altnagelvin.

The following are the facts:-

1. Altnagelvin heard a "rumour" from Paediatrics Intensive Care Unit that the "wrong fluids" had been used. This "rumour" emerged from a nurse in Paediatrics Intensive Care Unit responding to an enquiry from Altnagelvin's Ward Nurse on the child's state, on the Sunday.
2. In keeping with our own procedures, we carried out a Critical Incident Investigation. The child's unexpected collapse and subsequent death would trigger a Critical Incident Investigation, which has been our procedure since 1998.
3. A literature search on fluids was undertaken simultaneous to the Critical Incident Investigation.
4. Dr Nesbitt personally telephoned colleagues in several Hospitals regarding the use of perioperative fluids in children and informed them of the death of a child in Altnagelvin who had received no. 18 solution.
5. On 15/06/01 I wrote to the family offering my condolences and a meeting.
6. On 18/06/01 at a meeting with Dr Carson and other Medical Directors, Dr Fulton described the circumstances of the death and it was agreed that there should be regional guidelines.
7. In Mid June 01, Dr Fulton raised the matter with Dr McConnell who informed him he would speak to you about it. (On 05/07/01, Dr McConnell confirmed the discussion with you).
8. On 22/07/01 Dr Fulton spoke to yourself and informed you of the death. You suggested that CREST might review the guidelines.
9. On 26/07/01 I contacted you (via email) to personally advocate a regional review, following your conversation with Dr Fulton on 22/07/01.
10. On 03/09/01 I met with the family to describe the circumstances surrounding the death.
11. In January 02 whilst on a visit to Altnagelvin, Dr Nesbitt arranged for

you to view a presentation on Hyponatraemia.

12. On 01/05/02 Dr Nesbitt wrote to you enquiring if the death of a child some years previously from hyponatraemia in the RBHSC had been reported to the Department.

13. On 10/05/02 you replied that the Department had not been made aware of the first case either by the Royal or the Coroner.

I hope this is helpful.

Best Regards  
Stella

This email is confidential and intended solely for the use of the individual to whom it is addressed. Any views or opinions expressed are solely those of the author and do not necessarily represent those of Altnagelvin Hospitals Health and Social Services Trust.

If you are not the intended recipient, be advised that you have received this email in error and that any use, dissemination, forwarding, printing or copying of this email is strictly prohibited. If you have received this email in error please contact the sender.

Incoming Mail Disclaimer

Altnagelvin Hospital HSS Trust may monitor the content of emails sent and received via its network for the purposes of ensuring compliance with its policies and procedures.

For support please contact I.T. Department ; [REDACTED] Ext. [REDACTED]

Email IT [REDACTED]